The Future of COX-II Inhibitors: Market Challenges and Pipeline Initiatives

Introduction:

The non-steroidal anti-inflammatory drug (NSAID) market has been dominated by COX-II inhibitors for the past several years, but the majority of the success of these products has occurred in the US. This Market Brief analyzes the challenges facing COX-II inhibitors in Europe, as well as the keys to success for these products upon launch in Japan in 2004. Finally, the Brief evaluates novel compounds and mechanisms with the potential to directly challenge COX-II inhibitors in the future. 

Scope:

* Analysis highlights barriers to success for COX-II inhibitor sales in Europe, including regulatory issues, cost constraints, and clinical uncertainty 

* Evaluation of the current demand for COX-II inhibitors in Japan, where the products are not yet approved

 * Outlines the difficulties that companies will face in penetrating the Japanese market upon approval

* Analysis of three novel mechanisms of action with the potential to compete directly with COX-II inhibitors 

Report Highlights:

To date, the European market has been a commercial disappointment for the COX-II inhibitors; pharmaceutical companies must tailor their expectations and marketing strategies to this market 

COX-II inhibitors will finally be launched to the Japanese market, but specific challenges await interested players 

Novel challengers to the established COX-II inhibitors are on the way, but require further differentiation for market success 

Reasons to Purchase:

* Understand the factors that have held back the success of COX-II inhibitors in Europe 

* Identify the hurdles awaiting entrants to the Japanese COX-II inhibitor market, and the strategies required for success 

* Analyze the next wave of products with the potential to make a big splash in the NSAID market, for competitive intelligence or potential licensing 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a111